

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	785875-00021	Date of first issue: 28.06.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Orbifloxacin Liquid Formulation
1.2	Relevant identified uses of th	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Veterinary product
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD Kilsheelan Clonmel Tipperary, IE
	Telephone	:	353-51-601000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2
Specific target organ toxicity - repeated
exposure, Category 2, Eye

H361d: Suspected of damaging the unborn child. H373: May cause damage to organs through prolonged or repeated exposure if swallowed.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

:

Hazard pictograms

Signal word	:	Warning
Hazard statements	:	H361d Suspected of damaging the unborn child. H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	785875-00021	Date of first issue: 28.06.2016

Precautionary statements

Prevention:

P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label: Orbifloxacin

2

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.


Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Orbifloxacin	113617-63-3	Repr. 2; H361d	>= 3 - < 10
Lactic acid	50-21-5 200-018-0	Skin Corr. 1C; H314 Eye Dam. 1; H318 EUH071	>= 1 - < 3
Sodium hydroxide	1310-73-2 215-185-5 011-002-00-6	Met. Corr. 1; H290 Skin Corr. 1A; H314 Eye Dam. 1; H318	>= 1 - < 2





Orbifloxacin Liquid Formulation

	Number: 375-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016
		EUH014, EUH071

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed



Versio 4.4	on	Revision Date: 28.09.2024	-	OS Number: 5875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016	
Risks		: Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.				
4.3 In	ndicatio	on of any immediate	med	dical attention and	d special treatment needed	
٢	Treatm	ent	:	Treat symptomatically and supportively.		
SEC	TION	5: Firefighting meas	sur	es		
5.1 E	xtingu	ishing media				
S	Suitable	e extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (0 Dry chemical		
	Unsuita media	ble extinguishing	:	None known.		
5.2 S	pecial	hazards arising from	the	e substance or mi	xture	
	Specific fighting	c hazards during fire-	:	Exposure to com	bustion products may be a hazard to health.	
	Hazardous combustion prod- ucts		:	Carbon oxides Metal oxides		
5.3 A	dvice	for firefighters				
	Special for firefi	protective equipment ighters	:		e, wear self-contained breathing apparatus. tective equipment.	
	Specific ods	c extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do	

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions	

Environmental precautions	:	Avoid release to the environment.
		Prevent further leakage or spillage if safe to do so.
		Prevent spreading over a wide area (e.g. by containment or oil
		barriers).



Version 4.4	Revision Date: 28.09.2024	SDS Number: 785875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016
			ose of contaminated wash water. s should be advised if significant spillages ined.
6.3 Method	is and material for co	ontainment and clean	ing up
Methods for cleaning up		For large spills, ment to keep ma be pumped, stor Clean up remain bent. Local or nationa posal of this mat employed in the mine which regu Sections 13 and	ert absorbent material. provide dyking or other appropriate contain- aterial from spreading. If dyked material can be recovered material in appropriate container. In materials from spill with suitable absor- I regulations may apply to releases and dis- terial, as well as those materials and items cleanup of releases. You will need to deter- alations are applicable. 15 of this SDS provide information regarding mational requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling		Do not breathe mist or vapours.
C C		Do not swallow.
		Avoid contact with eyes.
		Avoid prolonged or repeated contact with skin.
		Handle in accordance with good industrial hygiene and safety
		practice, based on the results of the workplace exposure as- sessment
		Take care to prevent spills, waste and minimize release to the
		environment.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye
		flushing systems and safety showers close to the working
		place. When using do not eat, drink or smoke. Wash contami-
		nated clothing before re-use.
		The effective operation of a facility should include review of
		engineering controls, proper personal protective equipment,
		appropriate degowning and decontamination procedures,
		industrial hygiene monitoring, medical surveillance and the
		use of administrative controls.
7.2 Conditions for safe storage, i	inc	luding any incompatibilities

Requirements for storage	:	Keep in properly labelled containers. Store locked up. Store in
areas and containers		accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:



Version 4.4	Revision Date: 28.09.2024		DS Number: 35875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016
			Strong oxidizing Gases	agents
-	c end use(s) ic use(s)	:	No data available	2

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propylene glycol	57-55-6	TWA	25 ppm 79 mg/m3	FOR-2011- 12-06-1358
Orbifloxacin	113617-63- 3	TWA	0.2 mg/m3 (OEB 2)	Internal
Silicon dioxide	7631-86-9	TWA (respirable dust)	1,5 mg/m3 (Silica)	FOR-2011- 12-06-1358
Sodium hydroxide	1310-73-2	Т	2 mg/m3	FOR-2011- 12-06-1358

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
Silicon dioxide	Workers	Inhalation	Long-term systemic effects	4 mg/m3
Sodium hydroxide	Consumers	Inhalation	Long-term local ef- fects	1 mg/m3
	Workers	Inhalation	Long-term local ef- fects	1 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg dry weight (d.w.)
	Marine sediment	57,2 mg/kg dry



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Orbifloxacin Liquid Formulation

Version 4.4	Revision Date: 28.09.2024	SDS Number: 785875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016	
		Soil	weight (d.w.) 50 mg/kg dry weight (d.w.)	

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387
Filter type	:	Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	suspension
Colour	:	light brown
Odour	:	odourless
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Orbifloxacin Liquid Formulation

Ver 4.4	sion	Revision Date: 28.09.2024		S Number: 5875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016
		explosion limit / Lower bility limit	:	No data available	
	Flash p	oint	:	No data available	9
	Auto-ig	nition temperature	:	No data available)
	Decom	position temperature	:	No data available)
	рН		:	No data available)
	Viscosi Visc	ty :osity, kinematic	:	No data available)
	Solubili Wat	ty(ies) er solubility	:	No data available	3
	Partitio octanol	n coefficient: n- /water	:	No data available	•
	Vapour	pressure	:	No data available)
	Relative	e density	:	No data available)
	Density	,	:	No data available)
	Relative	e vapour density	:	No data available)
		characteristics icle size	:	No data available)
9.2	Other in	formation			
	Explosi	ves	:	Not explosive	
	Oxidizii	ng properties	:	The substance of	r mixture is not classified as oxidizing.
	Evapor	ation rate	:	No data available)
	Molecu	lar weight	:	No data available	

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.



Version 4.4	Revision Date: 28.09.2024		98 Number: 5875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016
10.3 Pos	ssibility of hazardous rea	acti	ons	
Haz	ardous reactions	:	Can react with st	rong oxidizing agents.
10.4 Coi	nditions to avoid			
Cor	nditions to avoid	:	None known.	
10.5 Inc	ompatible materials			
Mat	erials to avoid	:	Oxidizing agents	
	zardous decomposition phazardous decomposition			
SECTIC	N 11: Toxicological in	for	mation	
	rmation on likely routes of		Inhalation	ulation (EC) No 1272/2008
	osure		Skin contact Ingestion Eye contact	
Αςι	ite toxicity			
	classified based on availa	ble	information.	
<u>Cor</u>	nponents:			
	ifloxacin: te oral toxicity	:	LD50 (Rat): > 3.00	
Acu		•		tality observed at this dose.
			LD50 (Mouse): > 2 Remarks: No mor	2.000 mg/kg tality observed at this dose.
			LD50 (Dog): > 600 Symptoms: Vomit Remarks: No mor	
Acu	te inhalation toxicity		Remarks: No data	
	te dermal toxicity	:	Remarks: No data	
		-		
	te toxicity (other routes of ninistration)	:	LD50 (Rat): > 200 Application Route	
			LD50 (Mouse): 50 Application Route	
			LD50 (Rat): 233 n Application Route	
			LD50 (Mouse): 25	i0 mg/kg



	Revision Date: 28.09.2024	SDS Number: 785875-00021	
		Application	n Route: Intravenous
Lacti	c acid:		
Acute	e oral toxicity): > 2.000 mg/kg Based on data from similar materials
Acute	e inhalation toxicity	Method: O Assessme	
Acute	e dermal toxicity	Assessme toxicity	obit): > 2.000 mg/kg nt: The substance or mixture has no acute der Based on data from similar materials
Sodiu	um hydroxide:		
	inholation toxicity	· Assassma	nt: Corrosive to the respiratory tract.
	e inhalation toxicity	. Assessine	
Skin Not c <u>Prod</u> e Speci	corrosion/irritation lassified based on av <u>uct:</u> ies	ailable information : Rabbit	
Skin Not c Prod Speci Resu	corrosion/irritation lassified based on av <u>uct:</u> ies lt	ailable information	
Skin Not c Produ Speci Resu Com	corrosion/irritation lassified based on av <u>uct:</u> ies lt ponents:	ailable information : Rabbit	
Skin Not c Produ Speci Resu Com Orbif Speci Metho	corrosion/irritation lassified based on av <u>uct:</u> ies lt ponents: floxacin: ies od	ailable information : Rabbit : No skin irr : Rabbit : Draize Tes	itation
Skin Not c Prode Speci Resu Com Orbif	corrosion/irritation lassified based on av <u>uct:</u> ies lt ponents: floxacin: ies od	ailable information : Rabbit : No skin irr : Rabbit	itation
Skin Not c Produ Speci Resu Comj Orbif Speci Metho Resu	corrosion/irritation lassified based on av <u>uct:</u> ies lt ponents: floxacin: ies od	ailable information : Rabbit : No skin irr : Rabbit : Draize Tes	itation
Skin Not c Produ Speci Resu Comj Orbif Speci Metho Resu	corrosion/irritation lassified based on av <u>uct:</u> ies lt ponents: loxacin: ies od lt c acid: ies od lt	ailable information : Rabbit : No skin irr : Rabbit : Draize Tes : No skin irr : Rabbit : OECD Tes : Corrosive	itation
Skin Not c Produ Speci Resu Comj Orbif Speci Metho Resu Lacti Speci Metho Resu Resu	corrosion/irritation lassified based on av <u>uct:</u> ies lt ponents: loxacin: ies od lt c acid: ies od lt	ailable information : Rabbit : No skin irr : Rabbit : Draize Tes : No skin irr : Rabbit : OECD Tes : Corrosive	itation st itation st Guideline 404 after 1 to 4 hours of exposure

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Orbifloxacin Liquid Formulation

Vers 4.4	sion	Revision Date: 28.09.2024		DS Number: 5875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016			
	Produc	~+•						
	Specie			Rabbit				
	Result	5	÷	Mild eye irritation				
				-				
	Compo	onents:						
	Orbiflo	oxacin:						
	Specie	S	: Rabbit					
	Method	1	:	Draize Test				
	Result		:	Mild eye irritation				
	Lactic	acid:						
	Specie		:	Chicken eye				
	Remar	ks	:	Based on data fro	om similar materials			
	Result		:	Irreversible effect	s on the eye			
	Sodiur	n hydroxide:						
	Result	in nyai oxiac.		Irreversible effects on the eye				
	Remarks		:	Based on skin corrosivity.				
	Respiratory or skin sensi		atic	on				
		ensitisation ssified based on availa	able	information.				
	Respir	Respiratory sensitisation						
	Not cla	ssified based on availa	able	information.				
	Produc	<u>ct:</u>						
	Test Ty		:	Magnusson-Klign	nan-Test			
		ire routes	:	Dermal				
	Specie Result	S	÷	Guinea pig Not a skin sensitiz	70r			
	Result		•	NOL A SKIT SETSIL	201.			
	Compo	onents:						
	Orbiflo	oxacin:						
	Test Ty	/pe	:	Maximisation Tes	t			
		ire routes	:	Dermal				
	Specie: Result	S	÷	Guinea pig Not a skin sensiti	201			
	Result		-	Not a skin sensiti.	201.			
	Lactic	acid:						
	Test Ty		:	Buehler Test				
		ire routes	:	Skin contact				
	Specie: Result	5	÷	Guinea pig negative				
	Remar	ks	:		om similar materials			
	11/21							



Version 4.4	Revision Date: 28.09.2024		OS Number: 5875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016
Test ⁻	sure routes	:	Human repeat ins Skin contact negative	sult patch test (HRIPT)
	Germ cell mutagenicity Not classified based on availal		information.	
Com	oonents:			
Orbif	loxacin:			
Geno	toxicity in vitro	:	Test Type: Bacte Result: equivocal	rial reverse mutation assay (AMES)
			Test Type: Mouse Result: positive	e Lymphoma
			Test Type: Chron Test system: Hun Result: positive	nosomal aberration nan lymphocytes
Geno	toxicity in vivo	:	Test Type: Micron Species: Mouse Cell type: Bone m Application Route Result: negative	
			Test Type: unsch Species: Rat Cell type: Liver ce Application Route Result: negative	
Germ sessn	cell mutagenicity- As- nent	:	Weight of evidend cell mutagen.	ce does not support classification as a germ
Lacti	c acid:			
	toxicity in vitro	:	Method: OECD T Result: negative	rial reverse mutation assay (AMES) est Guideline 471 on data from similar materials
			Method: OECD T Result: negative	o mammalian cell gene mutation test est Guideline 476 on data from similar materials
				nosome aberration test in vitro Test Guideline 473

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Orbifloxacin Liquid Formulation

Version Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4 28.09.2024	785875-00021	Date of first issue: 28.06.2016

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Orbifloxacin: Species Application Route Exposure time NOAEL Result	 Rat Oral 2 Years 200 mg/kg body weight negative
Species Application Route Exposure time NOAEL Result	 Mouse Oral 2 Years 200 mg/kg body weight negative
Lactic acid: Species Application Route Exposure time Result Remarks	 Rat Ingestion 2 Years negative Based on data from similar materials
Reproductive toxicity	

Suspected of damaging the unborn child.

Components:

Orbifloxacin:

Effects on fertility :	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body weight Result: No adverse effects
Effects on foetal develop- : ment	Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight Result: No teratogenic effects, Embryotoxic effects and ad- verse effects on the offspring were detected only at high ma- ternally toxic doses
	Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral



ersion .4	Revision Date: 28.09.2024	SDS Number: 785875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016
		Embryo-fo Result: No toxic effect	oxicity Maternal: NOAEL: 20 mg/kg body weight etal toxicity: NOAEL: 60 mg/kg body weight effects on early embryonic development, Embryo is and adverse effects on the offspring were detect high maternally toxic doses, Reduced maternal ht gain
		Species: D Application Developme	Development log n Route: Oral ental Toxicity: LOAEL: 2,5 mg/kg body weight ects on postnatal development, Skeletal malfor-
Repro sessr	oductive toxicity - As- nent	: Some evid animal exp	ence of adverse effects on development, based o eriments.
	c acid: ts on foetal develop-	Species: M	Route: Ingestion
	Γ - single exposure lassified based on avai	lable information.	
	F - repeated exposure		
-		is (Eye) through p	prolonged or repeated exposure if swallowed.
-	uct: et Organs ssment	: Eye : May cause exposure.	e damage to organs through prolonged or repeated
Repe	ated dose toxicity		
Prod Spec NOAI LOAE Applie Expo	uct: ies EL	: Dog : 22,5 mg/kg : 37,5 mg/k : Oral : 30 Days : Gastrointes	·
Expo		: Dog : 75 mg/kg : Oral : 10 Days : Salivation,	Gastrointestinal disturbance, Vomiting
Speed	inn	0.04	

: Cat

Species

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Orbifloxacin Liquid Formulation

Version 4.4	Revision Date: 28.09.2024	SDS Number: 785875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016
Expos	ation Route sure time t Organs	: 45 mg/kg : Oral : 30 Days : Eye : Salivation, La disorders	achrymation, Gastrointestinal disturbance, Liver
Comp	onents:		
Orbifl	oxacin:		
Expos	E	: Rat : 20 mg/kg : 80 mg/kg : Oral : 3 Months : Testis, Liver,	Kidney, spleen
	E	: Mouse : 80 mg/kg : 250 mg/kg : Oral : 3 Months	
Expos	L L ation Route sure time t Organs toms	: Juvenile dog : 50 mg/kg : 250 mg/kg : Oral : 14 Days : Heart, Bone : Gastrointestin : mortality obse	nal disturbance erved
Expos	L L ation Route sure time t Organs	: Juvenile dog : 2 mg/kg : 3 mg/kg : Oral : 90 Days : Bone : No significan	t adverse effects were reported
		: Dog : 37,5 mg/kg : Oral : 30 Days	
	L L ation Route ure time	: Cat : 7,5 mg/kg : 22,5 mg/kg : Oral : 1 Months : Gastrointestin	nal disturbance

S MSD 🛕 Public

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Orbifloxacin Liquid Formulation

Version 4.4	Revision Date: 28.09.2024		DS Number: 5875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016
Spec NOA Appli Expo	Lactic acid: Species NOAEL Application Route Exposure time Remarks		Rat > 100 mg/kg Ingestion 13 Weeks Based on data	from similar materials
Species LOAEL Application Route Exposure time			Rat 886 mg/kg Skin contact 13 Weeks	

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Orbifloxacin:

Ingestion

: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash Remarks: May cause photosensitisation.

SECTION 12: Ecological information

12.1 Toxicity

12.1 Toxicity		
Components:		
Lactic acid:		
Toxicity to fish	:	LC50 (Danio rerio (zebra fish)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: Based on data from similar materials



Version 4.4	Revision Date: 28.09.2024	DS Number:Date of last issue: 06.04.202485875-00021Date of first issue: 28.06.2016	
Toxicity to algae/aquatic plants		ErC50 (Pseudokirchneriella subcapitata (green al mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials	gae)): > 100
		NOEC (Pseudokirchneriella subcapitata (green al mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials	gae)): > 100
Toxic	ity to microorganisms	EC50 : > 10 - 100 mg/l Exposure time: 3 h Method: OECD Test Guideline 209 Remarks: Based on data from similar materials	
12.2 Persi	,		
Components:			
Lactio	c acid:		
Biode	gradability	Result: Not readily biodegradable. Remarks: Based on data from similar materials	
12.3 Bioad	ccumulative potential		
<u>Comp</u>	oonents:		
Partiti	c acid: ion coefficient: n- ol/water	log Pow: -0,62	
12.4 Mobility in soil No data available			
12.5 Resu	Its of PBT and vPvB a	essment	
<u>Produ</u> Asses	uct: ssment	This substance/mixture contains no components of to be either persistent, bioaccumulative and toxic very persistent and very bioaccumulative (vPvB) a 0.1% or higher.	(PBT), or

12.6 Endocrine disrupting properties

Product:

Assessment	: The substance/mixture does not contain components consid- ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
------------	---



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	785875-00021	Date of first issue: 28.06.2016

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations				
13.1 Waste treatment methods				
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer. 			
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. 			

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.3 Transport hazard class(es)		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.4 Packing group		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good

Commission Regulation (EU) 2020/878



Orbifloxacin Liquid Formulation

Version 4.4	n Revision Date: 28.09.2024	SDS Number: 785875-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016		
R	ID	: Not regulated	as a dangerous good		
IN	IDG	: Not regulated	as a dangerous good		
IA	TA (Cargo)	: Not regulated	as a dangerous good		
IA	TA (Passenger)	: Not regulated	: Not regulated as a dangerous good		
14.5 Environmental hazards Not regulated as a dangerous good					
14.6 Special precautions for user Not applicable					
14.7 Maritime transport in bulk according to IMO instruments					

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	Conditions of restriction for the fol- lowing entries should be considered: Number on list 3
	Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli- cable to the placing on the market or not.

		not.
REACH - Candidate List of Substances of Very High	:	Not applicable
Concern for Authorisation (Article 59).		
REACH - List of substances subject to authorisation	:	Not applicable
(Annex XIV)		
Regulation (EC) on substances that deplete the ozone	:	Not applicable
layer		
Regulation (EU) 2019/1021 on persistent organic pollu-	:	Not applicable
tants (recast)		
Regulation (EU) No 649/2012 of the European Parlia-	:	Not applicable
ment and the Council concerning the export and import		
of dangerous chemicals		
Sovera III: Directive 2012/19/ELL of the European Parlian	nont	t and of the Council on

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	785875-00021	Date of first issue: 28.06.2016

working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

 The components of this product are reported in the following inventories:

 AICS
 : not determined

DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information Other information Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines. Full text of H-Statements H290 May be corrosive to metals. H314 Causes severe skin burns and eye damage. H318 Causes serious eye damage. Suspected of damaging the unborn child. H361d EUH014 Reacts violently with water. EUH071 Corrosive to the respiratory tract. Full text of other abbreviations Eye Dam. Serious eye damage Met. Corr. Corrosive to metals Reproductive toxicity Repr. : Skin Corr. Skin corrosion FOR-2011-12-06-1358 2 Norway. Occupational Exposure limits Long term exposure limit FOR-2011-12-06-1358 / TWA : Ceiling FOR-2011-12-06-1358 / T ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration as-

sociated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	785875-00021	Date of first issue: 28.06.2016

- Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Classification of the mixture:		Classification procedure:
Repr. 2	H361d	Calculation method
STOT RE 2	H373	Based on product data or assessment

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN